马蹄肾合并腹主动脉瘤的EVAR治疗:多中心经验
本文回顾性分析3国6中心2004–2013年10例合并马蹄肾的腹主动脉瘤患者接受EVAR治疗的资料。中位年龄67.5岁,中位瘤径57 mm,13条右肾动脉与13条左肾动脉均成功保留,9条峡部动脉被覆盖;全部动脉瘤成功隔绝,无内漏、血肿、伤口感染或肾衰竭。中位随访7年,3例于EVAR后7年死于心肌梗死,余7例情况良好,瘤囊中位缩小16.5 mm。作者认为EVAR对此类患者安全有效,短期与中期结果良好。
要点
- 马蹄肾合并腹主动脉瘤行EVAR时,副肾动脉与峡部动脉的血供保护是技术关键。
- 本组13条右肾动脉与13条左肾动脉全部成功保留,9条峡部动脉被覆盖。
- 全部动脉瘤成功隔绝,无内漏、血肿、伤口感染或肾衰竭,中位住院3.5天。
核心结论
- EVAR是治疗合并马蹄肾的腹主动脉瘤安全有效的血管内方案,短期与中期结果良好。
- 作者称本研究为其所知经EVAR成功治疗马蹄肾且无显著并发症的最大病例系列。
研究设计与样本
- 多中心回顾性病历回顾,纳入2004年1月至2013年12月收治的10例合并马蹄肾并接受EVAR治疗的腹主动脉瘤患者。
- 患者来自3个国家的6个中心,分析人口学、临床状态、病史、动脉瘤与肾脏解剖形态及手术结局。
主要发现
- 中位年龄67.5岁(范围47–81岁),中位主动脉瘤径57 mm(范围49–81 mm)。
- 共35条动脉提供肾脏灌注,其中13条右肾动脉与13条左肾动脉全部成功保留,9条峡部动脉被覆盖。
- 中位住院时间3.5天(范围1–14天),全部动脉瘤成功隔绝,无内漏、血肿、伤口感染或肾衰竭。
- 中位随访7年,3例于EVAR后7年死于心肌梗死,其余7例情况良好,瘤囊中位缩小16.5 mm。
临床怎么用
- 对合并马蹄肾的腹主动脉瘤患者,EVAR可作为安全有效的治疗选择,术前需重点评估副肾动脉与峡部动脉的解剖与血供。
- 围术期与随访中应关注内漏、伤口并发症及肾功能,并结合瘤囊变化评估疗效。
局限性
- 本研究为回顾性设计,样本量仅10例,且来自多中心,结果的外推需谨慎。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Horseshoe kidney is a congenital abnormality, with an incidence of 0.25% of the total population. Only 0.12% of patients who undergo an abdominal aortic aneurysm repair might also have a coexisting horseshoe kidney. We present a series of 10 cases auspiciously treated with an endovascular approach along with their respective patient evolutions. A review of the literature is also presented. MATERIALS AND METHODS: A retrospective review of the medical records (January 2004-December 2013) of 10 patients with abdominal aortic aneurysms and horseshoe kidney treated with endovascular repair was done. Patients were treated at 6 different centers in 3 different countries. Demographics, clinical status, medical history, anatomical morphology of the aneurysms and kidneys, as well as surgical outcomes were all analyzed. RESULTS: The median age was 67.5 years (range 47-81), and the median aortic aneurysmal diameter was 57 mm (49-81 mm). A total of 35 arteries provided renal perfusion. There were 13 right renal arteries and 13 left renal arteries, all successfully preserved, with 9 isthmus arteries covered. Median hospital stay consisted of 3.5 days (1-14 days). All aortic aneurysms were successfully excluded with no endoleaks, hematomas, wound infections, or renal failure. During a median follow-up of 7 years, 3 patients died of myocardial infarction 7 years after endovascular aortic repair (EVAR), and the other 7 patients are doing well, with a median aneurysm reduction size sac of 16.5 mm. CONCLUSIONS: Endovascular repair is a safe and efficient endovascular option for the treatment of patients presenting concomitant aortic aneurysm and horseshoe kidney, with excellent short- and medium-term outcomes. To our knowledge, our study represents the largest series of cases with horseshoe kidney successfully treated via EVAR without significant complications.
引用
- Fabiani MA, González-Urquijo M, Riambau V, et al. EVAR Approach for Abdominal Aortic Aneurysm with Horseshoe Kidney: A Multicenter Experience. Ann Vasc Surg. 2019. PMID: 30731220. doi:10.1016/j.avsg.2018.10.042
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。